- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940231
Prospective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular Classification
Prospective Observational Validation of a Vision-Based Model for Integrated Histopathological and Molecular Classification of Gliomas From Intraoperative Specimen Photographs
This prospective observational cohort study will evaluate the diagnostic performance and workflow feasibility of a prespecified locked artificial intelligence model that analyzes smartphone-based natural-light gross images of fresh surgical tissue together with participant age. Approximately 400 consecutive adults undergoing initial surgery for suspected intracranial adult-type diffuse glioma will be enrolled at Beijing Tiantan Hospital, Capital Medical University, between July and September 2026. Images will be acquired before frozen-section processing according to a standardized operating procedure. Model outputs will be generated in silent mode and will not be shown to the surgical or pathology teams and will not alter diagnosis or treatment. The locked model score will be compared with the final IDH mutation reference standard derived from permanent histopathology, immunohistochemistry, and indicated molecular testing. The primary objective is to estimate patient-level discrimination for IDH-mutant versus IDH-wildtype tumors. Secondary objectives include fixed-threshold performance, precision-recall performance, calibration, end-to-end technical success, and prespecified model abstention, if an abstention rule is locked before enrollment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligible participants will be enrolled consecutively, and a screening log will document all exclusions. Fresh ex vivo tumor tissue will be photographed before freezing. Images will be deidentified and linked through a participant-surgery-specimen-image hierarchy. The locked SNAP-IDH model will segment the tumor region of interest, permit blinded quality confirmation or editing, and combine frozen iBOT image features with age using a radial basis function support vector machine. The output is a research model score rather than a clinically calibrated absolute risk. A score of frozen yoden or will be classified as IDH-mutant. Model outputs will remain hidden from all clinical decision makers. No retraining, hyperparameter tuning, threshold selection, or recalibration will use the prospective cohort. Diagnostic accuracy will be analyzed at the participant level. Image-acquisition, segmentation, inference, and reference-standard failures will be retained in the study flow and reported separately from complete-case diagnostic performance.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Yinyan Wang
- Phone Number: +86 13581698953
- Email: tiantanyinyan@126.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- Recruiting
- Beijing Tiantan Hospital
-
Contact:
- Yinyan Wang
- Phone Number: +86 13581698953
- Email: tiantanyinyan@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Consecutive adults undergoing initial surgery for suspected intracranial adult diffuse glioma at the participating facility
Description
Inclusion Criteria
- Adults aged 18 years or older at enrollment.
- A newly presenting intracranial lesion is radiologically suspected to be an adult-type diffuse glioma, and the participant is scheduled to undergo initial surgical resection or biopsy at a participating site.
- The planned index surgery includes an attempt to collect fresh tumor tissue for standardized natural-light gross-image acquisition before freezing.
- Participants must be able and willing to provide written informed consent before any study-specific procedure.
Exclusion Criteria
- Two or more radiologically distinct intracranial lesions identified on preoperative imaging.
- Radiotherapy or chemotherapy directed at the current intracranial lesion before the index surgery.
- Known recurrent disease or a previous tumor-directed surgical procedure for the current lesion.
- Primary spinal cord tumor, including a cervical spinal cord tumor.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Prospective Silent-Validation Cohort. Consecutive adults undergoing initial surgery for suspected i
|
Consecutive adults undergoing initial surgery for suspected intracranial adult-type diffuse glioma will undergo standardized research imaging of fresh surgical tissue. Locked model outputs will not influence routine surgery, frozen-section assessment, permanent pathology, molecular testing, or treatment. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient-Level Area Under the Precision-Recall Curve of the Locked SNAP-IDH Score for IDH Mutation Status
Time Frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Area under the precision-recall curve (AUPRC) calculated using one locked SNAP-IDH score per patient and the final reference-standard isocitrate dehydrogenase (IDH) mutation status, with IDH-mutant status as the positive class. AUPRC ranges from 0 to 1, with higher values indicating better performance. |
From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient-Level Sensitivity of SNAP-IDH for IDH Mutation Status at the Prespecified Threshold
Time Frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Percentage of patients with reference-standard isocitrate dehydrogenase (IDH)-mutant status classified as IDH-mutant by SNAP-IDH at the prespecified, locked classification threshold. Sensitivity is calculated as true positives divided by the sum of true positives and false negatives, multiplied by 100. |
From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
|
Patient-Level Specificity of SNAP-IDH for IDH Mutation Status at the Prespecified Threshold
Time Frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Percentage of patients with reference-standard isocitrate dehydrogenase (IDH)-wildtype status classified as IDH-wildtype by SNAP-IDH at the prespecified, locked classification threshold. Specificity is calculated as true negatives divided by the sum of true negatives and false positives, multiplied by 100. |
From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
|
Patient-Level Brier Score of the Locked SNAP-IDH Predicted Probability for IDH Mutation Status
Time Frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Mean squared difference between each patient's locked SNAP-IDH predicted probability of isocitrate dehydrogenase (IDH) mutation and the final reference-standard status, coded as 1 for IDH-mutant and 0 for IDH-wildtype. The Brier score ranges from 0 to 1, with lower values indicating lower prediction error. |
From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BT26901
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.